The Week in Review: Golden Meditech Raises $40 Million

Golden Meditech raised $40 million in private equity for its autologous blood recovery medical device JV; Boehringer Ingelheim held the formal opening of an R&D center in Shanghai; 3SBio in-licensed the China rights to an anti-rejection drug from Isotechnika; China PharmaHub will distribute radioactive glass spheres in China to treat liver cancer; Xiamen Innovax Biotech’s vaccine for hepatitis B was effective in a Phase III trial; Lotus Pharma began a Phase I trial of R-Bambuterol®, an asthma treatment; and Aoxing Pharma received SFDA approval to begin a clinical trial of a treatment for opioid addiction. More details…. Stock Symbols: (HKEX: 801) (NSDQ: SSRX) (TSX: ISA) (OTCBB: WRLC) (OTCBB: LTUS) (NYSE Amex: AXN)